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Abstract
Background A novel transoral incisionless fundoplication
(TIF) procedure using the EsophyX system with Serosa-
Fuse fasteners was designed to reconstruct a full-thickness
valve at the gastroesophageal junction through tailored
delivery of multiple fasteners during a single-device
insertion. The safety and efﬁcacy of TIF for treating gas-
troesophageal reﬂux disease (GERD) were evaluated in a
prospective multicenter trial.
Methods Patients (n = 86) with chronic GERD treated
with proton pump inhibitors (PPIs) were enrolled. Exclu-
sion criteria included an irreducible hiatal hernia[2 cm.
Results The TIF procedure (n = 84) reduced all hiatal
hernias (n = 49) and constructed valves measuring 4 cm
(2–6 cm) and 230  (160 –300 ). Serious adverse events
consisted of two esophageal perforations upon device
insertion and one case of postoperative intraluminal
bleeding. Other adverse events were mild and transient. At
12 months, aggregate (n = 79) and stratiﬁed Hill grade I
tight (n = 21) results showed 73% and 86% of patients
with C50% improvement in GERD health-related quality
of life (HRQL) scores, 85% discontinuation of daily PPI
use, and 81% complete cessation of PPIs; 37% and 48%
normalization of esophageal acid exposure; 60% and 89%
hiatal hernia reduction; and 62% and 80% esophagitis
reduction, respectively. More than 50% of patients with
Hill grade I tight valves had a normalized cardia circum-
ference. Resting pressure of the lower esophageal sphincter
(LES) was improved signiﬁcantly (p\0.001), by 53%.
EsophyX-TIF cured GERD in 56% of patients based on
their symptom reduction and PPI discontinuation.
Conclusion The 12-month results showed that EsophyX-
TIF was safe and effective in improving quality of life and
for reducing symptoms, PPI use, hiatal hernia, and
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DOI 10.1007/s00268-008-9594-9esophagitis, as well as increasing the LES resting pressure
and normalizing esophageal pH and cardia circumference
in chronic GERD patients.
Introduction
The need for a long-term treatment of gastroesophageal
reﬂux disease (GERD) has become increasingly apparent
during the past decade and a half as a result of the growing
prevalence and incidence of this chronic disease [1–6]. The
likelihood of developing GERD increases with the severity
of anatomic change and dysfunction of the gastroesopha-
geal (GE) junction, which represents the primary defense
against reﬂux of gastric content into the esophagus [7–12].
Restoration of the antireﬂux competence of the GE junc-
tion at the anatomic and physiologic levels is critical for
effective long-term treatment of GERD [2].
Antireﬂux surgery has been shown to be more effective
in terms of patient satisfaction, clinical outcome, and health
care cost reduction than pharmacologic antisecretory
therapies in the long-term management of chronic GERD
[13–16]. However, side effects of the antireﬂux fundopli-
cation procedures frequently compromise otherwise
excellent postsurgical results [15, 17]. Persistent dyspha-
gia, inability to belch and vomit, and increased bloating
and ﬂatulence are common side effects that may persist for
more than 6 months following surgery and prove to be
difﬁcult to treat [13, 18–21]. To minimize the risk of
chronic complications, a variety of factors must be taken
into account, including the technical aspects of the opera-
tion [20, 22]. ‘‘Tailoring’’ the valve seems to restore the
physiology of the GE junction more adequately, allowing
air to be vented from the stomach without jeopardizing the
efﬁcacy of the antireﬂux barrier [12, 23].
A novel transoral incisionless device was developed in
an attempt to mimics antireﬂux surgery through con-
structing a valve at the GE junction, restoring the angle of
His, and reducing a small hiatal hernia with fewer side
effects. The EsophyX system with SerosaFuse fasteners
(EndoGastric Solutions, Redmond, WA, USA) was
designed to reconstruct a valve through tailored delivery of
multiple fasteners during a single-device insertion [24].
The EsophyX device and the corresponding transoral in-
cisionless fundoplication (TIF) procedure were developed
based on the current knowledge and understanding of the
anatomic and physiologic functions of the GE junction that
was derived from extensive research with open and lapa-
roscopic antireﬂux surgery [25–28]. The safety and
efﬁcacy of the EsophyX-TIF procedure were initially
demonstrated by 12-month results from a feasibility study
with 19 patients [29]. This article presents results at 6 and
12 months from a prospective multicenter trial with 86
patients that was intended to further evaluate the safety and
efﬁcacy of the TIF procedure using the EsophyX system
with SerosaFuse fasteners.
Patients and methods
The study, designed as a prospective multicenter trial, was
conducted internationally at seven clinical centers under a
common protocol approved by each center’s ethics com-
mittee. Informed consent was obtained before enrolling
patients in the study.
Patient selection
The study population consisted of patients 18 to 80 years of
age with chronic GERD symptoms ([6 months) responsive
to proton pump inhibition (PPI) therapy, as judged by
GERD health-related quality of life (HRQL) scores of B 12
while on PPI therapy, whose symptoms recurred upon dis-
continuation of PPI therapy for 14 days (GERD-HRQL
score C 20 or a difference of C 10 between the scores on
and off PPIs). Pathologic esophageal acid exposure was
conﬁrmed by 48-hour pH-metry using the wireless Bravo
pH system (Medtronic, Shoreview, MN, USA) [30]. To be
included, patients were also required to have a deteriorated
GE junction with Hill grade II, III, or IV [26]. Brieﬂy, the
Hill grades were deﬁned as follows.
• Grade I valves: presence of a prominent tissue fold
surrounding the endoscopic shaft
• Grade II valves: presence of a moderately prominent
tissue fold; rarely opens with respiration and closes
promptly
• Grade III valves: a barely present fold; fails to close
around the endoscope
• Grade IV valves: lack of a muscular fold; lumen of
esophagus stays open all the time, allowing the
squamous epithelium to be viewed from below
The exclusion criteria were severe reﬂux esophagitis grade
D in the Los Angeles classiﬁcation [31]; body mass index
(BMI) C 35 kg m
-2; other esophageal diseases, including
biopsy-proven Barrett’s esophagus, esophageal motility
disorders, esophageal stricture, esophageal ulcer, delayed
gastric emptying, irreducible hiatal hernia of[2 cm; or
previously failed antireﬂux surgery.
During the initial screening phase, patients were evalu-
ated for their medical history including GERD medication
usage, and they completed the GERD-HRQL questionnaire
while on PPI therapy. The use of PPIs was then discon-
tinued for 14 days, and other GERD medications, such as
histamine receptor antagonists (H2RA) or antacids, was
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123discontinued for 7 and 2 days, respectively. While off all
GERD medications, the GERD-HRQL questionnaire was
readministered, and esophageal pH was assessed over a
48-hour period.
This evaluation was repeated at 3, 6, and 12 months after
the procedure. The assessment at the time of screening and
at 6 and 12 months also included upper gastrointestinal (GI)
endoscopy and optional biopsy. Manometry and barium
swallow radiography were performed at screening and at
6 months but were optional at 12 months.
Procedure details
The TIF procedure using the EsophyX device was designed
to create full-thickness serosa-to-serosa plications and
construct valves 3 to 5 cm in length and 200  to 300  in
circumference [24]. The procedures were performed fol-
lowing a standard TIF1.0 protocol under general anesthesia
with either nasal or transoral intubation by a team of two
physicians (surgeons and/or gastroenterologists) [24, 29].
The ﬁrst physician controls the implantation of fasteners
using the EsophyX device, and the second operates the
endoscope and ensures continuous direct visualization.
The device is inserted transorally into the esophagus with
the patient in the left lateral position. The hiatal hernia, if
present, is reduced by returning the squamocolumnar
junction to its natural position below the diaphragm using a
built-in vacuum invaginator. During a single insertion, a
valve similar to that created through antireﬂux surgery is
reconstructed by retraction of full-thickness plications and
tailored placement of multiple fasteners circumferentially
around the GE junction starting on the greater curve side of
the valve [29].
Patients were instructed to consume a liquid diet during
the ﬁrst 2 weeks and a soft diet during the following
4 weeks. PPIs were discontinued 7 days after the proce-
dure. In the event of symptom recurrence requiring
medication, a ‘‘step-down’’ protocol was employed; and
patients were returned to their preprocedure dose of PPIs
and then weaned from them if possible. There was no TIF
retreatment allowed in the present study.
Safety assessment
The incidences of anticipated and unanticipated serious and
nonserious adverse events were carefully recorded. Serious
adverse events were deﬁned as complications necessitating
hospitalization and medical or surgical intervention.
Adverse events and symptoms were recorded and catego-
rizedusingtheMedical DictionaryforRegulatoryActivities
(MedDRA) classiﬁcation system developed by the Interna-
tional Conference on Harmonisation (ICH) (http://www.
meddramsso.com).
Effectiveness assessment
The primary effectiveness endpoint was patient quality of
life assessed by the validated 10-question GERD-HRQL
questionnaire evaluating heartburn-related symptoms and
patient satisfaction using a 0 to 5 Visual Analogue Scale
[32]. The total GERD-HRQL scores were calculated by
summing the responses to nine questions [33]; possible
scores ranged between 0 (no symptoms) and 45 (worst
symptoms). A C 50% improvement in the total GERD-
HRQL scores compared to the baseline off PPIs was con-
sidered clinically signiﬁcant [34, 35]. The heartburn score
was calculated by summing the responses to the ﬁrst six
questions. Absent or rare heartburn (scores of B 2 to each
of the six questions, or a total score of B 12) was indica-
tive of heartburn elimination. Patient satisfaction with their
current health condition was evaluated based on question
10 as either ‘‘satisﬁed,’’ ‘‘neutral,’’ or ‘‘dissatisﬁed’’ [32].
Regurgitation was assessed as present or absent by a sep-
arate direct question.
Secondary effectiveness endpoints were PPI usage,
esophageal acid exposure, hiatal hernia size, reﬂux
esophagitis grade, valve Hill grade, and lower esophageal
sphincter (LES) resting pressure. These endpoints allowed
thorough, complete evaluation of the competence of the
antireﬂux barrier.
The use of PPIs and other GERD medications, such as
H2RA and antacids, was recorded. ‘‘Daily’’ usage of PPIs
corresponded to a double dose, full dose, or half dose taken
daily for more than 50% of the total number of days during
the follow-up period. ‘‘Occasional’’ or ‘‘on-demand’’ usage
was deﬁned as less than a half dose or any daily dose of
PPIs taken for less than 50% of the total number of days
during the follow-up period. The designation ‘‘none’’ was
used when not a single dose of PPIs was taken during the
speciﬁed period. Reduction of usage from daily to none or
occasional was considered clinically signiﬁcant.
Esophageal acid exposure corresponded to the percent-
age of total monitoring time at pH\4; it was normal if it
was B 5.3 [36, 37] or signiﬁcantly improved if it was
reduced by C 30% compared to that pre-TIF, a rate sufﬁ-
cient to eliminate symptoms [38]. During the 48-hour
assessment, patients were encouraged to engage in their
usual activities [36, 39]. Periods of poor signal reception
and capsule displacement to the stomach or intestine were
excluded from calculations upon review and recommen-
dation of a validation panel.
Upper GI endoscopy was performed to assess the pres-
ence and size of a hiatal hernia. A reduction in hiatal hernia
size of at least 50% compared to that pre-TIF was con-
sidered clinically signiﬁcant. The endoscopy examination
also assessed reﬂux esophagitis following the Los Angeles
classiﬁcation [31] and the geometrical aspects of the TIF
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(in centimeters) from the apex of the fundus to the valve lip
[40] and circumference, deﬁned as the distance in degrees
between the two most distant fasteners. The valve geom-
etry was evaluated based on the adherence to the
endoscope as tight, moderate, or loose and the Hill grade
[26], as described above. A one-grade reduction in
esophagitis or Hill grade at 12 months compared to that
pre-TIF was considered clinically signiﬁcant.
Cardia circumference was evaluated retrospectively
using cardia circumference measurement software and
static retroﬂexed images [41]. A total of 41 patients with
clear retroﬂexed views of the cardia before and 12 months
after TIF and the known caliber of the gastroscope were
considered eligible for cardia circumference measure-
ments. A total of 15 measurements (three images measured
ﬁve times each) were taken for each patient and follow-up
period after the validated protocol [41] and were used to
calculate the mean cardia circumference. A mean cardia
circumference of\34.3 mm was considered normal [41].
Esophagealmanometrywasperformedintheusualfashion
using a stationary pull-through technique [42].A LES resting
pressure of 10 to 40 mmHg was considered normal [43].
Values post-TIF represented the latest follow-up measure.
Effectiveness endpoints were evaluated after discontinu-
ation of PPIs for at least 14 days before TIF and
postoperative follow-up visits at 3, 6, and 12 months.
Patientsservedastheirowncontrols,andtheoutcomevalues
at each follow-up were compared with those before TIF.
A global assessment of all outcome measures was per-
formed for each patient to determine the long-term
effectiveness of the EsophyX-TIF procedure in curing
GERD. Patients were considered ‘‘completely cured’’ if
they had no more heartburn or regurgitation, normal or
signiﬁcantly reduced esophageal acid exposure, eliminated
esophagitis, and reduced hiatal hernia. Patients were con-
sidered ‘‘cured’’ from GERD if they demonstrated
clinically signiﬁcant alleviation of their symptoms (C50
reduction) and discontinued all PPI therapy. Patients were
considered ‘‘improved’’ if they required only occasional
PPI therapy and had reduced heartburn. Patients with
‘‘ongoing GERD’’ showed no alleviation of their symptoms
and required daily PPIs.
A web-based data entry system (Simpliﬁed Clinical
Data Systems, Milford, NH, USA) with case report forms
was employed for real-time data capture at each site. All
data were veriﬁed against source documents through reg-
ular onsite monitoring.
Statistical analysis
Data were analyzed by an independent statistician using
SAS statistical software version 8.0 (SAS Institute, Cary,
NC, USA). Continuous variables, summarized by medians
and ranges, were considered to represent the population
main trends because of the generally skewed data distri-
bution (as indicated by asymmetrical ranges around the
medians). Categorical variables were summarized as
counts and percentages. The p values for changes at 6 or
12 months compared to pre-TIF were calculated using
Wilcoxon’s signed rank, sign, McNemar’s test, or the
Mann-Whitney test. Values of p\0.05 were considered
signiﬁcant.
The results at 12 months were stratiﬁed into three cat-
egories depending on the Hill grade and TIF valve
adherence: Hill grade I, tight; Hill grade II, moderate; Hill
grade III/IV, loose. Patients with valves that did not ﬁt into
the listed categories were excluded from the stratiﬁcation
analysis. Differences among Hill grade groups and follow-
up visits were tested for signiﬁcance using Spearman’s
rank correlation or the Kruskal-Wallis test of the equality
of medians.
Percentage reduction in esophagitis grade was also
calculated without the patients taking daily or occasional
PPIs at 12 months to avoid a type 1 error, as the usage of
medication represented a confounding variable to the effect
of TIF on esophagitis improvement.
Predictors of clinical effectiveness at 12 months were
evaluated through nonparametric Spearman’s rank corre-
lation coefﬁcient between anatomic and pathophysiologic
variables with continuous and ordinal values. Spearman’s
coefﬁcient (q) ranged from -1 to + 1, with negative values
indicating that one variable tended to increase as the other
decreased and positive values indicating a positive increase
of two variables.
Results
Patient characteristics
A total of 86 patients were enrolled between April and
December 2006 from seven clinical centers in Belgium
(ﬁve), Germany (one), and Italy (one), with 4 to 27 patients
per center. Three patients (3%) had inclusion/exclusion
violations for which they were granted exemptions. Among
those patients, one had a pathological 10-question GERD-
HRQL score on PPIs of 14 but a borderline score off PPIs
of 20 and therefore a difference between scores of only 6;
and two patients had a BMI of 36. In addition, later vali-
dation of the pH reports identiﬁed one patient with a long
recording period in the stomach resulting from premature
dislodgement of the Bravo capsule on the second day. The
exclusion of this gastric period resulted in changing the
values of esophageal acid exposure to normal on the worst
day (3% time pH\4 and 13.1 DeMeester score). This
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pH-metry data.
The enrolled 86 patients were 19 to 73 years old (median
44 years, mean ± SD 44.0 ± 12.5 years) (Table 1). Over-
all, the patients had suffered from GERD for a median
6 years (1–33 years) and were on continuous daily PPI
medication for 4 years (1–14 years). The median GERD-
HRQL and heartburn scores pre-TIF increased (worsened)
after discontinuation of PPIs from 9 (0–22) to 24 (11–38)
and from 7 (0–19) to 21 (10–30), respectively. Before TIF,
100% of patients were taking either full-dose or half-dose
PPIs on a daily basis (Fig. 1). While taking PPIs, 31 (37%)
patients were satisﬁed, 25 (30%) neutral, and 27 (33%)
dissatisﬁed with their health condition compared to 5 (6%)
who were satisﬁed, 4 (5%) neutral, and 74 (89%) dissatis-
ﬁed after discontinuation of PPIs. Esophagitis was present
in 81% of patients, and 58% had a hiatal hernia with a
median size of 1 cm (1–3 cm) (Table 1). Hiatal hernias of
3 cm in four patients were successfully reduced perioper-
atively. Biopsy revealed gastritis in 47% of patients and
gastric polyps in 9%. Most of the gastroesophageal valves
were Hill grade II or III (Fig. 2). The mean of 77 LES
resting pressures was 13.1 mmHg (4–30 mmHg). Three
patients had LES resting pressures below the lower limit of
10 mmHg, but ineffective ‘‘hypotonic’’ esophageal motility
disorder was ruled out because they had normal esophageal
body amplitude pressure and peristalsis.
Procedure details
The median procedure time was 77 minutes (28–
208 minutes). A median of 14 (7–22) SerosaFuse fasteners
Table 1 Patient characteristics at screening
No. patients 86
Female/male 29/57 (34%/66%)
Age (years) 44 (19–73)
BMI (kg m
-2) 25.2 (17.1–36.1)
Hiatal hernia 49/85 (58%)
Esophagitis 70 (81%)
Gastritis 21/45 (47%)
GERD history
GERD duration (years) 6 (1–33)
[11 years 11 (13%)
6–10 years 34 (40%)
3–5 years 27 (31%)
6 months to 2 years 14 (16%)
No. Patients on PPIs 86 (100%)
PPI use duration (years) 4 (1–14)
[11 years 4 (5%)
6–10 years 21 (24%)
3–5 years 41 (48%)
\2 years 20 (23%)
Values represent medians (range) or counts (%)
BMI: body mass index; GERD: gastrointestinal reﬂux disease; PPIs:
proton pump inhibitor
Fig. 1 Usage and dosage of proton pump inhibitors. TIF: transoral
incisionless fundoplication
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(55/84) of procedures were conducted by ﬁve teams of two
gastroenterologists and the remaining 35% by two teams of
one surgeon and one gastroenterologist. Altogether, 89% of
the procedures were accomplished using a single device.
The TIF valves had a median length of 4 cm (2–6 cm) and
a circumference of 230  (160 –300 ). All 49 hiatal hernias
were reduced, including the 4 that measured 3.0 cm.
Hospitalization stay was 1 day for all but one of the
patients; the exception was a patient who experienced
intraluminal bleeding and was hospitalized for 5 days (see
later).
Safety assessment
The most common adverse event was musculoskeletal pain
in the left shoulder for up to 1 month reported by 16 (18%)
patients (Table 2). Other events included abdominal pain
(15%), sore throat (8%), nausea (8%), and epigastric pain
(7%). Difﬁculty swallowing associated with a sore throat
were reported as dysphagia and lasted up to 1 week after
the procedure. All of these nonserious adverse events were
mild and resolved spontaneously. Chronic diarrhea, gas
bloat, and/or nausea were notably absent.
Three serious adverse events (SAEs) occurred in the
study. The ﬁrst was perforation of the proximal esophagus
during advancement of the device without ensuring ade-
quate visualization. The procedure was discontinued, and
the injury was immediately repaired with surgical suture
following the standard care protocol for managing esoph-
ageal perforations [44]. The patient was discharged after
6 days with no sequelae. The second SAE was perforation
that occurred during attempted device insertion into the
narrow hypopharynx of a patient with Turner’s syndrome.
The investigators recommended this patient based on
adequate endoscopic access, but the esopharynx space
proved to be insufﬁcient to allow introduction of the
device/endoscope assembly. The perforation was con-
ﬁrmed by computed tomography and surgically repaired
after 2.5 hours. The patient was discharged after 21 days.
The third SAE consisted of post-TIF intraluminal bleeding
and a reported decrease in hemoglobin of 70 g L
-1. The
patient underwent blood transfusion with 4 units of blood,
and the bleeding was stopped by applying clips endo-
scopically and injecting ﬁbrin glue. The patient was
discharged after 5 days and remained in the study.
A total of 81 (96%) patients at 6 months and 79 (94%)
patients at 12 months (of the 84 treated) completed the
follow-up assessment tests and were included in the clini-
cal effectiveness analysis. Seven patients were lost to
follow-up (8%): Two patients with esophageal injury
exited the study immediately and later underwent a lapa-
roscopic Nissen fundoplication (LNF); two patients exited
the study before the 3-month follow-up (one underwent
LNF); one patient failed to return at the 6-month follow-up
visit but returned for the 12-month visit; and three patients
could not be contacted or were unable to make their
12-month visit. The patients lost to follow-up were inclu-
ded in the safety analysis but excluded from the clinical
assessment because of the lack of data.
Clinical effectiveness at 12 months
The GERD-HRQL scores improved signiﬁcantly, by 68%,
compared to those before TIF and off PPIs (Table 3). A
clinically signiﬁcant improvement in GERD-HRQL scores
wasachievedby73%ofpatients(Table 3).Heartburnscores
were signiﬁcantly reduced in 75% of patients compared to
thoseoffPPIs(Table 3).Regurgitationexperiencedwhileon
and off PPIs was signiﬁcantly (p = 0.02) reduced in 55%
and 59% of patients, respectively. Complete symptom
elimination(GERD-HRQLscore B 12)wasexperiencedby
75% of patients; and 65% of patients were satisﬁed, 12%
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Fig. 2 Hill grade distribution of the valves
Table 2 Adverse events after the EsophyX-TIF procedure catego-
rized by the MedDRA classiﬁcation system and grouped by their
duration
Adverse event B1 Week 1 Week to 1 month [1 Month
Musculoskeletal pain 8 (9%) 8 (9%)
Abdominal pain upper 8 (9%) 4 (5%) 1 (1%)
Pharyngolaryngeal pain 6 (7%) 1 (1%)
Nausea 6 (7%) 1 (1%)
Epigastric pain 4 (5%) 2 (2%)
Application site bleeding 5 (6%)
Pyrexia 3 (4%)
Dysphagia 3 (4%)
Diarrhea 2 (2%)
Vomiting 2 (2%)
Values represent number of patients experiencing an adverse event
for each of the time periods
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Cessation of daily PPIs was reported by 85% of patients
(Table 4). The esophageal acid exposure time was signiﬁ-
cantly reduced or normalized in 61% of patients (Table 5).
The mean LES resting pressure was increased signiﬁ-
cantly (p\0.001), by 53%, to 18.2 mmHg (4–43, n = 75)
(Fig. 3).
Upper GI endoscopy revealed that the TIF valves (Fig. 4)
were 2.5 cm (1–5 cm) in length and 180  (0 –280 ) cir-
cumference. Most of the TIF valves were Hill grade I or II
(Fig. 2, Table 6). Among the valves with Hill grade III/IV
before TIF, 54% experienced a clinically signiﬁcant
improvement to Hill grade I or II. Gastritis and polyps were
absent. Hiatal hernias present in 36% of patients at
12 months were reduced in size in 60% of cases (Table 6);
the reduction was associated with a reduction of esophagitis
in 57% of those patients. Among patients with esophagitis
before TIF, 62% experienced a signiﬁcant grade reduction
and 40% total elimination. Among those patients with
healed esophagitis, 68% had grade A before TIF, 24% had
grade B, and 10% had grade C. Esophagitis elimination in
67% of cases resulted from eliminating the hiatal hernia and
reducing the Hill grade. Comparison of the results among
all three follow-up periods (3, 6, and 12 months) revealed
no signiﬁcant differences.
Stratiﬁcation analysis showed that the 21 patients with
Hill grade I tight TIF valves at 12 months experienced 75%
improvement in GERD-HRQL scores, 86% cessation of
daily PPIs, 48% normalization of esophageal acid expo-
sure, and more than 80% reduction in their hiatal hernias
and esophagitis (Table 7). The improvements obtained by
these patients were signiﬁcantly better than those obtained
in patients with Hill grade III/IV valves in terms of
esophageal acid normalization, hiatal hernia reduction,
esophagitis reduction and elimination, and cardia circum-
ference size and normalization. Among-group comparison
revealed that the patients in all three groups had the same
level of GE junction deterioration at screening (median Hill
grade III), a similar median age (p = 0.3), BMI (p = 0.4),
sex and race ratio (p = 0.3), and duration of GERD and
PPI usage (p[0.05); they differed signiﬁcantly (p\0.05)
in the occurrence and size of their hiatal hernias and the
LES resting pressure: 16.4 ± 1.4 for Hill grade I,
13.0 ± 1.3 for Hill grade II, and 11.7 ± 1.1 for Hill grade
III/IV (p = 0.045).
Global assessment revealed that 56% of patients
(n = 45) were ‘‘cured’’ of their GERD based on the clin-
ically signiﬁcant reduction of their heartburn and complete
cessation off PPIs, which were accompanied with nor-
malization or signiﬁcant reduction of esophageal acid
exposure in 80% of cases (Fig. 5). Among the cured
patients, 24% (n = 19) were ‘‘completely cured,’’ as they
experienced total elimination of symptoms, esophagitis,
and hiatal hernia as well as normalization of esophageal
Table 3 GERD health-related
quality of life scores and
symptoms
HRQL: health-related quality of
life; TIF: transoral incisionless
fundoplication
a Deﬁned by a total score
of B12 with each of the six
questions evaluated as rare
(score B2)
Parameter Pre–TIF (n = 82) 6 Months Post-TIF
(n = 81)
12 Months Post-TIF
(n = 79)
GERD-HRQL score
Median (range) off PPIs 24 (11–38) 5 (0–24) 7 (0–30)
Median % reduction vs. pre-TIF off PPIs 80% 68%
p \0.0001 \0.0001
No. reduced by C50% 62 (77%) 58 (73%)
No. eliminated 65 (80%) 59 (75%)
Median (range) on PPIs 9 (0–22) – –
Median % reduction vs. pre-TIF on PPIs 50% 22%
p \0.05 [0.05
Heartburn score
Median (range) off PPIs 21 (10–30) 4 (0–19) 6 (0–26)
Median % reduction vs. pre-TIF off PPIs 79% 67%
p \0.0001 \0.0001
No. reduced by C50% 62 (77%) 59 (75%)
No. eliminated
a 70 (86%) 61 (77%)
Median (range) on PPIs 7 (0–19) – –
Median % reduction vs. pre-TIF on PPIs 43% 22%
p \0.05 [0.05
Regurgitation
No. off PPIs 60 (74%) 24 (30%) 25 (32%)
No. eliminated 37 (62%) 34 (59%)
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123acid exposure. Most of these patients had Hill grade I or II
valves. The ‘‘improved’’ group consisted of 22% of
patients who experienced 80% reduction of their symp-
toms, were off daily PPIs, and had reduced hiatal hernia or
esophagitis. The remaining 22% of patients had ‘‘ongoing’’
GERD as they continued to experience GERD symptoms
and required daily PPI therapy.
Correlation analysis at 12 months revealed a signiﬁcant
relation (q[0.5, p\0.001) between the valve’s Hill
grade and hiatal hernia size, esophagitis grade, LES resting
pressure, and cardia circumference (Table 8). Esophageal
acid exposure correlated most signiﬁcantly with hiatal
hernia size.
Discussion
The patient population participating in this study suffered
from severe chronic GERD. Most of the patients had had
GERD for more than 6 years, experienced frequent and
severe heartburn and regurgitations, and used PPIs at a
daily dose of 20 to 80 mg for more than 3 years. The high
prevalence of hiatal hernia, esophagitis, and gastritis
reﬂected an advanced level of the disease. Gastritis and
gastric polyps have been associated with prolonged PPI use
[45–47]. Upper GI endoscopy conﬁrmed that deterioration
of the GE junction (Hill grade II or III) appeared con-
comitantly with the presence of high esophageal acid
exposure, esophagitis, and/or hiatal hernia. Patients with
similar characteristics are typically referred for antireﬂux
surgery [15, 17] or treated with increasing doses of PPIs
[48, 49].
The two esophageal perforations experienced in this
study were associated with device insertion. They under-
line the caution required during this stage of transoral
surgery [50] and the need for careful pretherapeutic patient
assessment [23]. In approximately 330 TIF cases that have
been performed worldwide to date, these were the only two
Table 4 Use of proton pump inhibitors (PPIs), histamine receptor
antagonists (H2RA), and antacids before and after the EsophyX-TIF
procedure
Medication No. Daily Occasional None
PPIs
Pre-TIF 86 86 (100%) 0 0
6 Months 81 14 (17%) 11 (14%) 56 (69%)
12 Months 79 12 (15%) 13 (16%) 54 (68%)
H2RA
Pre-TIF 86 3 (3%) 1 (1%) 82 (95%)
6 Months 81 0 1 (1%) 80 (99%)
12 Months 79 0 5 (6%) 74 (94%)
Antacids
Pre-TIF 86 0 18 (21%) 68 (79%)
6 Months 81 0 21 (26%) 60 (74%)
12 Months 79 0 23 (29%) 56 (71%)
Any GERD medication
Pre-TIF 86 86 (100%) 0 0
6 Months 81 14 (17%) 25 (31%) 42 (52%)
12 Months 79 12 (15%) 29 (37%) 38 (48%)
Usage was deﬁned as ‘‘daily’’ when C half dose was taken for C50%
of the preceding follow-up period; as ‘‘occasional’’ when B half dose
taken for\50% of the preceding follow-up period; and as ‘‘none’’
when no medication was taken during the speciﬁed period
Values represent counts (%)
Table 5 Esophageal pH monitoring
Parameter Pre-TIF
(n = 82)
6 Months
Post-TIF
(n = 81)
12 Months
Post-TIF
(n = 71)
a
Percentage of time pH\4
Median (range) 10 (3–67) 7 (1–29) 7 (0–22)
Median % reduction 31 33
p \0.001 0.02
Normalized
b 33 (41%) 26 (37%)
Signiﬁcantly
reduced
c
or normalized
46 (57%) 43 (61%)
DeMeester score
Median (range) 34 (11–222) 24 (4–107) 28 (1–76)
Median % reduction 28 24
p \0.001 \0.001
a Data were missing for eight patients because of technical problems
with Bravo (n = 5), contraindications due to other health problems
(n = 2), or refusal (n = 1)
b Deﬁned by pH\4 for B 5.3% of the total monitoring time [36]
c Deﬁned by a delta of C 30% compared to baseline off PPIs
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P < 0.01
Post-TIF (n = 75)
Fig. 3 Resting pressure of lower esophageal sphincter (LES) deter-
mined by manometry before and after the EsophyX-TIF procedure
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123known instances of esophageal injury upon device insertion
[51]. They might have been avoided by careful device
introduction under continuous endoscopic visualization and
by excluding patients with abnormal or unusually narrow
esophageal anatomy. Additional reﬁnement in the design of
the device may also help reduce this risk. The reported
instance of intraluminal bleeding at one fastener site was
the only serious complication that resulted directly from
the TIF procedure. Tissue compression inherent in the
device design and delivery method most likely accounts for
the low incidence of intraluminal bleeding.
The side effects reported after the TIF procedure were
few, mild, and transient. Shoulder pain, which was reported
by 18% of patients, is typically associated with antireﬂux
laparoscopic surgery and results from indirect or direct
irritation of the phrenic nerve and the resulting dermatome
response [52]. The abdominal pain reported in 15% of
patients most likely resulted from insufﬂation during the
procedure and was proportional to the extent of insufﬂation
and procedure duration. Epigastric pain experienced by 7%
of patients was most likely associated with transmural se-
rosal fastening. Pharyngolaryngeal pain, reported as sore
throat by 8% of patients, was assumed to be caused by
insertion of the 18 mm device and its repetitive rotations
around the longitudinal axis during the procedure. Nausea
present in 7% of patients could result from insufﬂation,
anesthesia, or manipulation of tissue at the GE junction that
possibly stressed the vagus nerve. The postoperative dys-
phagia experienced by 4% resulted from swelling at the GE
junction and resolved within 7 days without intervention.
Chronic side effects typically associated with laparoscopic
fundoplication (e.g., dysphagia, gas bloat, diarrhea) [19,
20, 53] were notably absent after TIF. The difference in the
incidence of these complications probably resulted from
the absence of any surgical dissection and of wrapping the
greater gastric curvature around the esophagus, both of
Fig. 4 Endoscopic images of
gastroesophageal valves from
two patients who had Hill grade
IV valves, esophagitis A, and a
2 cm hiatal hernia before TIF.
At 6 and 12 months post-TIF
both patients had Hill grade I
valves, no hiatal hernia, and no
esophagitis
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123which contribute to the observed side effects after Nissen
fundoplication [17, 20, 54].
The results at 12 months supported the clinical effec-
tiveness of the TIF procedure in treating patients with
chronic GERD. The overall median improvement in
GERD-HRQL of 68% reported at 12 months post-TIF
resulted in a complete symptom resolution in 75% of
patients. Although quality of life is subjective, patients
typically request treatment for their heartburn rather than
for their esophagitis or abnormal esophageal acid exposure
[2, 3, 15]. Although the reduction in GERD symptoms at
12 months was similar to that obtained while on PPIs, TIF
resulted in higher patient satisfaction than with PPI ther-
apy. The elimination of daily PPI dependence in 85% of
patients at 12 months after the EsophyX-TIF procedure
was also encouraging.
The TIF procedure was shown to be effective in
reducing small hiatal hernias (B2 cm). EsophyX has been
identiﬁed as the only transoral device that is capable of
reducing small hiatal hernias [50]. It was hypothesized that
the durability of the reduction of hiatal hernias through TIF
was accomplished by tightening the phrenoesophageal
membrane, which is one of the intrinsic components of the
antireﬂux barrier [55, 56]. The TIF reduction of small
hiatal hernias was durable in 60% of patients and con-
tributed to the signiﬁcant reduction in esophageal acid
exposure and esophagitis in the patients. Several studies
have demonstrated similar beneﬁcial changes in anatomy
and physiology of the GE junction after eliminating a hiatal
hernia, especially in terms of healing esophagitis, normal-
ization of esophageal acid exposure, and increasing the
LES resting pressure [9–11].
Restoration of the deteriorated GE junctions to Hill
grade I tight valves resulted in elimination of GERD
symptoms, total cessation of daily PPI use, and healing of
esophagitis in more than 80% of patients. The level of
effectiveness achieved at 12 months by 27% of patients
with Hill grade I tight valves was signiﬁcantly correlated
with reduction of the hiatal hernia, normalization of the
cardia circumference, and the increase in LES resting
pressure. The demonstrated signiﬁcant correlation between
the quality of anatomic reconstruction and the improve-
ment in clinical and pathophysiologic outcome measures
provides compelling evidence to support the ability of the
TIF procedure to improve the antireﬂux competence of the
GE junction.
Although the exact underlying mechanism of TIF valves
remains under investigation, the total resolution of GERD
symptoms and the healing of esophagitis achieved in most
of the patients in this study, especially in those with Hill
grade I tight valves, are strong evidence indicating that the
TIF valves contributed to a better mechanical barrier,
thereby preventing GE reﬂux. Moreover, the durable and
effective repair of small hiatal hernias, the signiﬁcantly
increased LES resting pressure, the narrowed cardia, and
the re-created acute angle of His support the ability of the
TIF procedure to enhance the competence of the antireﬂux
barrier. The fact that preoperative hiatal hernias were
smaller and less common among patients with Hill grade I
tight valves (44%) than those with Hill grade II moderate
valves (67%) and Hill grade III/IV loose valves (71%) at
12 months suggested that patients with small (B 2 cm) or
no hiatal hernia might be the best initial candidates for this
procedure as they experienced the best outcome in terms of
esophagitis healing and symptom relief.
The 12-month results demonstrated that the level of
clinical and anatomic improvements obtained following the
TIF procedure was sustained over time. Technical exper-
tise, the quality of the tailored valve, and careful
postprocedure patient management have been identiﬁed as
key factors for achieving the highest level of anatomic
repair of the GE junction through TIF. Similar factors have
been identiﬁed for successful antireﬂux surgeries [57–59].
Table 6 Endoscopic evaluation
Parameter Pre-TIF
(n = 82)
6 Months
Post-TIF
(n = 81)
12 Months
Post-TIF
(n = 77)
a
Hill grade
I 0 22 (29%) 24 (33%)
II 35 (45%) 42 (55%) 26 (36%)
III 34 (44%) 10 (13%) 18 (25%)
IV 9 (12%) 3 (4%) 5 (7%)
Hiatal hernia
None 33 (41%) 58 (72%) 49 (64%)
1 cm 11 (14%) 7 (9%) 12 (16%)
2 cm 33 (41%) 14 (17%) 10 (13%)
3 cm 4 (5%) 2 (3%) 6 (8%)
Reduced 35/47 (74%)
p\0.001
27/45 (60%)
p\0.001
Eliminated 29/47 (62%) 22/45 (49%)
Esophagitis
None 14 (17%) 37 (46%) 35 (45%)
Grade A 31 (38%) 26 (32%) 22 (29%)
Grade B 27 (33%) 14 (17%) 14 (18%)
Grade C 10 (12%) 3 (4%) 5 (6%)
Grade D 0 1 (1%) 1 (1%)
Reduced
b 42/67 (63%)
p\0.001
39/63 (62%)
p\0.001
Eliminated
b 26/67 (39%) 25/63 (40%)
a Data are missing for two patients whose examinations were con-
traindicated because of other health problems
b After excluding patients taking daily PPIs, at 6 and 12 months
esophagitis was reduced in 61% and 58% of patients and eliminated
in 39% and 37% of patients, respectively
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123Conclusion
The 12-month results of this prospective multicenter study
showed that the TIF procedure using the EsophyX system
with SerosaFuse fasteners was effective in improving
quality of life, reducing symptoms, decreasing the need for
daily PPIs, reducing esophageal acid exposure, increasing
LES resting pressure, and promoting healing of esophagitis
in patients with chronic GERD. The obtained improvement
in clinical and pathophysiologic outcomes correlated sig-
niﬁcantly with the quality of the anatomic reconstruction.
The side effects related to TIF were few and transient, and
the two esophageal perforations resulting from device
introduction underline the caution needed during this phase
of transoral surgery. The clinical improvements obtained at
12 months after the EsophyX-TIF1.0 procedure in the
study population dominated by patients with advanced
stages of GERD were encouraging. The tailored fastener
placement technique (TIF2.0) is expected to further
improve on these results and support the use of EsophyX-
TIF for the treatment of GERD.
Note
Based on the results obtained in the present study, the
EsophyX/SerosaFuse system was cleared by the U.S.
Food and Drug Administration (FDA) in September 2007
and is indicated for use in transoral tissue approximation,
full-thickness plication and ligation in the GI tract, for
the treatment of symptomatic chronic GERD in patients
who require and respond to pharmacologic therapy, and
for use in narrowing the GE junction and reducing hiatal
hernia of B 2 cm in patients with symptomatic chronic
GERD.
Table 7 Clinical effectiveness
at 12 months stratiﬁed into three
groups depending on the
anatomic characteristics of TIF
valves deﬁned by Hill grade and
adherence
a
a Valves not ﬁtting into either
category were excluded from
stratiﬁcation
b Patients taking PPIs were
excluded
c Normalized cardia
circumference if\34.3 mm
[41]
* The p values for among-group
comparisons reﬂect the exact
global test (Spearman’s rank
correlation) for the trend of
lower Hill grade associated with
better outcome
Parameter Hill grade I
tight (n = 21)
Hill grade II
moderate (n = 21)
Hill grade III/IV
loose (n = 14)
p*
GERD-HRQL scores—improved by C 50% 18 (86%) 17 (81%) 11 (79%) 0.330
Heartburn—eliminated 19 (90%) 17 (81%) 10 (71%) 0.122
PPI use—none 17 (81%) 18 (86%) 7 (50%) 0.091
Esophageal pH—normalized 48% 25% 33% 0.014
Hiatal hernia
None post-TIF 18 (86%) 14 (67%) 5 (36%) 0.002
None pre-TIF 12 (56%) 7 (33%) 4 (29%) 0.014
Reduced 8/9 (89%) 10/14 (71%) 3/10 (30%) 0.250
Eliminated 7/9 (78%) 7/14 (50%) 3/10 (30%) 0.290
Esophagitis
None post-TIF 15 (71%) 9 (43%) 5 (36%) 0.001
None pre-TIF 3 (14%) 2 (10%) 3 (21%) 0.400
Reduced
b 12/15 (80%) 14/19 (74%) 4/11 (36%) 0.010
Eliminated
b 9/15 (60%) 7/19 (37%) 3/11 (27%) 0.002
Cardia circumference (mm)
Post-TIF 32.8 37.5 40.4 0.001
Pre-TIF 43.3 46.8 41.3 0.050
Normalized
c 9/16 (56%) 4/12 (33%) 1/12 (8%) 0.040
Cured
56%
Ongoing 
GERD
22%
Improved
22%
Fig. 5 Study population divided into three groups depending on the
degree of cure from gastroesophageal reﬂux disease (GERD) based on
the long-term clinical effectiveness of EsophyX-TIF. Cured: patients
demonstrated clinically signiﬁcant alleviation of their symptoms and
discontinued their usage of proton pump inhibitor (PPI) therapy.
Improved: patients required only occasional PPI therapy and had
reduced heartburn. Ongoing GERD: patients showed no alleviation of
their symptoms and required daily usage of PPIs. Among the cured
patients, 24% were ‘‘completely cured’’ of GERD based on total
elimination of heartburn and regurgitation, completely healed esoph-
agitis, reduced hiatal hernia, and normalized or signiﬁcantly reduced
esophageal acid exposure
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